课题基金 / 基金详情

Covid-19 PPE - PeRSo Powered Air-Purifying Respirator (PAPR)

Covid-19 PPE - PeRSo Powered Air-Purifying Respirator (PAPR)
Covid-19 PPE - PerSo 动力空气净化呼吸器 (PAPR)
批准号:
58010
负责人:
金额:
$6.36万
依托单位:
依托单位国家:
英国
项目类别:
Feasibility Studies
财政年份:
2020
资助国家:
英国
项目状态:
已结题
起止时间:
2020 至 --
关键词:

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
我们的项目旨在大量开发和生产一种价格合理且可重复使用的带兜帽和集成口罩的空气净化呼吸器(PeRSo),这将使NHS一线员工和医护人员在治疗患者时保持安全,有效和舒适的工作。PeRSo的想法是补充甚至取代目前使用的外科口罩或呼吸器口罩(N95/FFP3),这些口罩在全球范围内供不应求,供应链仍面临重大挑战。当使用者在受污染的环境中工作时,个人防护装置将为使用者提供个人保护。PeRSo将通过呼吸管和呼吸罩向用户提供清洁空气,以便用户在当前的Covid-19大流行中安全,自信,舒适和有效地照顾患者。通过这个项目,我们可以大规模生产PeRSo,使其成为一线员工的标准配备。在2019冠状病毒病大流行期间,我们的NHS和一线工作人员正在努力挽救生命,我们相信这款产品可以在我们最需要他们的时候帮助他们保持安全和弹性。
英文摘要
Our project aims to develop and manufacture at high volumes an affordable and reusable powered air-purified respirator with hood and integrated mask (the PeRSo) which will enable frontline NHS staff and healthcare workers to remain safe, work effectively and in comfort whilst treating patients. The idea is for the PeRSo to supplement and even replace the current use of surgical masks or respirator masks (N95/FFP3) which are in short supply globally and with significant challenges continuing in the supply chain.The PeRSo will provide personal protection to the user when working in a contaminated environment. The PeRSo will provide clean air to the user via breathing tube and respirator hood so that the user can safely, confidently, comfortably and effectively look after patients in the current Covid-19 pandemic. Through this project we can scale to a high-volume manufacture of PeRSo so they become standard issue to staff on the frontline.Our NHS & frontline staff are working incredibly hard to save lives during the Covid-19 pandemic and we believe this product can help them stay safe and resilient when we need them most.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
芽孢杆菌TR19-1对魔芋腐皮镰刀菌拮抗机理研究
1H/19F多核MRI术中可视化免疫抑制巨噬细胞定位脑胶质瘤浸润边界
ATPIF1调节线粒体膜电位影响靶向CD19 CAR-T细胞抗肿瘤活性的作用及机制
  • 批准号:
    2026JJ80001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    钟根深
  • 依托单位:
CD19/BCMA双靶向CAR-NK细胞治疗难治性SLE:作用机制与临床前转化研究
  • 批准号:
    2026JJ81339
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    谢希
  • 依托单位: